BXRX.Q Stock Overview
A pharmaceutical company, develops and commercializes products for hospital and other acute care related settings. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Baudax Bio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.000001 |
| 52 Week High | US$0.062 |
| 52 Week Low | US$0.000001 |
| Beta | -11.87 |
| 11 Month Change | -99.00% |
| 3 Month Change | -99.00% |
| 1 Year Change | -100.00% |
| 33 Year Change | -100.00% |
| 5 Year Change | -100.00% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Baudax Bio stock down after pricing $6.2M equity offering
Aug 30Baudax Bio to get US patent linked to pain drug Anjeso
Aug 22Baudax Bio GAAP EPS of -$1.05 beats by $0.22, revenue of $0.3M
Aug 11Cosette Pharmaceuticals appoints Rick Casten as CFO
Jul 06Baudax Bio: Looking For A Turnaround In Strong COVID-19 Headwinds
Sep 09A First Look At Baudax Bio
May 30Baudax Bio EPS misses by $0.08, misses on revenue
May 05Baudax Bio's Anjeso shows efficacy in pain management for total knee arthroplasty
Apr 26Have Insiders Been Buying Baudax Bio, Inc. (NASDAQ:BXRX) Shares?
Feb 17
Baudax Bio EPS of $0.62
Nov 09Baudax Bio: Why I'm Catching This Falling Knife
Nov 03Shareholder Returns
| BXRX.Q | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | 1.6% | 2.2% |
| 1Y | -100.0% | 10.0% | 31.7% |
Return vs Industry: BXRX.Q underperformed the US Pharmaceuticals industry which returned 10.8% over the past year.
Return vs Market: BXRX.Q underperformed the US Market which returned 31.1% over the past year.
Price Volatility
| BXRX.Q volatility | |
|---|---|
| BXRX.Q Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: BXRX.Q's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine BXRX.Q's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2019 | 9 | Gerri Henwood | www.baudaxbio.com |
Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care related settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with other non-NSAID analgesics. It also develops BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMB, which is in phase I clinical trial, as well as a proprietary blockade reversal agent; and BX3000, a NMB reversal agent that is in preclinical studies.
Baudax Bio, Inc. Fundamentals Summary
| BXRX.Q fundamental statistics | |
|---|---|
| Market cap | US$52.00 |
| Earnings (TTM) | -US$59.20m |
| Revenue (TTM) | US$1.27m |
0.0x
P/S Ratio0.0x
P/E RatioIs BXRX.Q overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BXRX.Q income statement (TTM) | |
|---|---|
| Revenue | US$1.27m |
| Cost of Revenue | US$7.01m |
| Gross Profit | -US$5.74m |
| Other Expenses | US$53.46m |
| Earnings | -US$59.20m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.13 |
| Gross Margin | -452.32% |
| Net Profit Margin | -4,665.25% |
| Debt/Equity Ratio | -436.4% |
How did BXRX.Q perform over the long term?
See historical performance and comparison